戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 iffered from the expression profile in renal oncocytoma.
2 is up-regulated in RCC and down-regulated in oncocytoma.
3 highly similar but benign counterpart, renal oncocytoma.
4 pe 2 papillary, chromophobe, TFE3, TFEB, and oncocytoma.
5 ignant renal cell carcinoma (RCC) and benign oncocytoma.
6 ing diversion of tumor progression to benign oncocytomas.
7 y be a molecular basis for the occurrence of oncocytomas.
8 rentiation between clear cell carcinomas and oncocytomas.
9 f 12 (25%) clear cell RCCs, but 0 of 4 renal oncocytomas.
10 in was detected primarily in chromophobe RCC/oncocytomas.
11 mples, including nonpapillary, papillary and oncocytomas.
12  multiple chromosomal arms in CDCs and renal oncocytomas.
13 , concordantly with the persistence of human oncocytomas.
14 %) sporadic renal tumors: 2 of 7 (29%) renal oncocytomas, 1 of 9 (11%) chromophobe RCCs, 4 of 11 (36%
15 x10(-3) mm(2)/s; p<0.05 and in patients with oncocytoma - 2.75+/-0.27x10(-3) mm(2)/s vs. 2.11+/-0.25x
16        The mean and peak perfusion levels of oncocytoma (373.9 mL/min/100 g +/- 99.2 and 512.3 mL/min
17 (208.0 mL/min/100 g +/- 41.1, P = .001), and oncocytoma (373.9 mL/min/100 g +/- 99.2, P < .001).
18 d MITF), chromophobe kidney cancer (5%), and oncocytoma (5%).
19 enal tumors of different cell types: 7 renal oncocytomas, 9 chromophobe renal cell carcinomas (RCCs),
20 of the renal cell carcinoma, 5 patients with oncocytoma and 5 patients with angiomyolipoma (AML).
21 er excluding benign renal neoplasia (such as oncocytoma and angiomyolipoma), alterations of BAP1, FLC
22                         In particular, renal oncocytoma and chromophobe RCC, which present the most s
23 the molecular classification of chRCC, renal oncocytoma and pRCC.
24  of mtDNA variation has been demonstrated in oncocytoma and prostate cancer, while mtDNA variation ha
25 echanisms of OXPHOS exist in chRCC and renal oncocytoma and that expression levels of ETC complex sub
26 itary kidney cancer syndromes, like familial oncocytoma and the Birt-Hogg-Dube syndrome, have been id
27 can be used to differentiate solid RCCs from oncocytomas and characterize the histologic subtypes of
28 167 primary human tumors that included renal oncocytomas and non-clear cell renal cell carcinomas (nc
29 most of the tested markers in seven of eight oncocytomas and one of 69 clear cell carcinomas.
30 ondria with negative charge potential (e.g., oncocytomas and other benign/indolent lesion) and do not
31 he five false-positive masses included three oncocytomas and two Bosniak category 3 cystic lesions.
32 04 to April 2019 were searched for keywords "oncocytoma" and "oncocytic neoplasm" and compared with s
33 in BHD(d/+) mice including oncocytic hybrid, oncocytoma, and clear cell with concomitant loss of hete
34 l RCC, papillary RCC, chromophobe RCC, renal oncocytoma, and normal.
35 enal tissues, including normal kidney, renal oncocytoma, and renal cell carcinomas (RCC).
36 f 170 clear cell RCCs, 57 papillary RCCs, 49 oncocytomas, and 22 chromophobe RCCs were evaluated for
37 uding pyelonephritis, renal cysts, adenomas, oncocytomas, and normal kidney, did not express the MN/C
38 carcinomas, six chromophobe carcinomas, four oncocytomas, and one angiomyolipoma were analyzed.
39 phobe renal cell carcinoma (chRCC) and renal oncocytoma are closely related, rare kidney tumors.
40 group of nonconcerning lesions (15/36), with oncocytoma as the predominant histologic type (n = 6).
41  To assess the reliability of a diagnosis of oncocytoma based on image-guided percutaneous renal mass
42 RCCs were distinguished from chromophobe RCC/oncocytomas based on large-scale gene expression pattern
43 complex in tumors, is up-regulated in benign oncocytoma but down-regulated in RCC.
44 y chromophobe renal cell carcinoma and renal oncocytoma but not by clear cell renal cell carcinoma or
45 ive phosphorylation (OXPHOS) system in renal oncocytoma, but are less frequently observed in chRCC.
46 e further distinguished from chromophobe RCC/oncocytomas by overexpression of vimentin and class II m
47 athological subtypes of renal tumors (benign oncocytoma, clear cell, papillary, and chromophobe RCC)
48                                              Oncocytomas demonstrate higher perfusion levels than RCC
49                              Chromophobe RCC/oncocytomas displayed similar expression profiles, inclu
50 ilies (chromophobe: amylases 1A, 1B, and 1C; oncocytoma: general transcription factors 2H2, 2B, 2C, a
51                                   One of the oncocytoma hallmarks is the lack of respiratory complex
52              Converting carcinomas in benign oncocytomas has been suggested as a potential anti-cance
53 iomyoma renal cell carcinoma, familial renal oncocytoma, hereditary nonpolyposis colon cancer, and me
54 gnificantly between clear cell carcinoma and oncocytoma in any phase (P = .2081-.6000).
55 ic neoplasm (n = 28), and indeterminate with oncocytoma in differential (n = 2).
56 ized as oncocytoma or likely oncocytoma were oncocytomas in 16 of 17 masses (94%) based on surgical p
57  RCCs including papillary, nonpapillary, and oncocytomas in order to determine whether allelic loss c
58  of clear cell RCCs was greater than that of oncocytomas in the corticomedullary (125 HU vs 106 HU, P
59                                     In renal oncocytomas, LOH of 1q occurred in approximately 30% of
60 th the most common benign renal tumor, renal oncocytomas, may be overtreated with surgical resection
61 139 patients; 149 masses were categorized as oncocytoma (n = 107), likely oncocytoma (n = 12), oncocy
62  categorized as oncocytoma (n = 107), likely oncocytoma (n = 12), oncocytic neoplasm (n = 28), and in
63 even segments), clear cell (three segments), oncocytoma (nine segments), and papillary type 2 (two se
64 omophobe, and 10 unclassified carcinomas; 16 oncocytomas; nine angiomyolipomas).
65               Biopsied masses categorized as oncocytoma or likely oncocytoma were oncocytomas in 16 o
66 ients with RCC but is nearly undetectable in oncocytoma, other tumors, and urinary tract inflammation
67 t helped to discriminate clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC with accu
68 in the discrimination of clear cell RCC from oncocytoma, papillary RCC, and chromophobe RCC.
69 ma (RCC) specimens (chromophobe, clear cell, oncocytoma, papillary type 1, and papillary type 2) usin
70      Mean enhancement of clear cell RCCs and oncocytomas peaked in the corticomedullary phase; mean e
71 d tumor fate from adenomas and carcinomas to oncocytomas-rare, predominantly benign tumors characteri
72 l chromophobe renal cell carcinoma and renal oncocytoma seem to originate from the A-type intercalate
73 e 26 benign small renal masses (including 18 oncocytomas, seven lipid-poor angiomyolipomas, and one h
74 ns; 24 (12%), chromophobe adenomas; 14 (7%), oncocytomas; six (3%), lipid-poor angiomyolipomas; and 1
75 bserved on arms 8p, 14q, 19q, and 21q in the oncocytomas studied.
76 es in clear cell, papillary, chromophobe RCC/oncocytoma, TCC and Wilms' subtypes.
77                          Clear cell RCCs and oncocytomas tended to be hypervascular, chromophobe lesi
78 e chromophobe RCC, five sarcomatoid RCC, two oncocytomas, three transitional cell carcinomas (TCC) of
79 ared segments ranged from a 6.1-kb deletion (oncocytomas) to a 208.3-kb deletion (chromophobes).
80  family of neoplasms ranging from the benign oncocytoma, to the indolent papillary and chromophobe ca
81 rcinomas (RCC), one chromophobe RCC, and two oncocytomas using cDNA microarrays.
82 s versus cystic RCC, adenoma versus RCC, and oncocytoma versus granular cell RCC.
83  imaging-based diagnosis of solid RCC versus oncocytoma was 0.854.
84                  The mean tumor perfusion of oncocytoma was higher than that of clear cell RCC (P < .
85 uided percutaneous biopsy diagnosis of renal oncocytoma was reliable.
86                              The MIN in some oncocytomas was of the RER+ (replication error) type I p
87 hree families classified with familial renal oncocytoma were identified with BHD mutations, which rep
88 d masses categorized as oncocytoma or likely oncocytoma were oncocytomas in 16 of 17 masses (94%) bas
89 ations, chromophobes, clear-cell tumors, and oncocytomas were composed exclusively of noncoding DNA.
90                                    All seven oncocytomas were considered to be malignant with both me
91                                     When the oncocytomas were excluded, specificities increased to 83
92 llecting duct carcinomas (CDCs) and 13 renal oncocytomas were studied using highly informative micros
93 were malignant, and 19 (20%)-including seven oncocytomas-were benign.
94 d to derive a cohort of 298 cases of RCC and oncocytoma with preoperative multiphasic multidetector C
95  the management of renal masses diagnosed as oncocytomas with image-guided percutaneous biopsy.
96 and papillary features, chromophobe RCC, and oncocytoma; with ccRCC being the most prevalent.